Search

Your search keyword '"Dandoy, Christopher E."' showing total 710 results
Start Over Author "Dandoy, Christopher E."
710 results on '"Dandoy, Christopher E."'

3. Clinical Characteristics and Outcomes of COVID-19 in Pediatric and Early Adolescent and Young Adult Hematopoietic Stem Cell Transplant Recipients: A Cohort Study

Author

Bhatt, Neel S, Sharma, Akshay, St Martin, Andrew, Abid, Muhammad Bilal, Brown, Valerie I, Diaz Perez, Miguel Angel, Frangoul, Haydar, Gadalla, Shahinaz M, Herr, Megan M, Krem, Maxwell M, Lazarus, Hillard M, Martens, Michael J, Mehta, Parinda A, Nishihori, Taiga, Prestidge, Tim, Pulsipher, Michael A, Rangarajan, Hemalatha G, Williams, Kirsten M, Winestone, Lena E, Yin, Dwight E, Riches, Marcie L, Dandoy, Christopher E, and Auletta, Jeffery J

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Stem Cell Research - Nonembryonic - Human, Stem Cell Research, Pediatric Research Initiative, Pediatric, Transplantation, Cancer, Clinical Research, Regenerative Medicine, Prevention, Good Health and Well Being, Adolescent, COVID-19, COVID-19 Testing, Child, Cohort Studies, Hematopoietic Stem Cell Transplantation, Humans, Oxygen, Young Adult, Covid-19, Early adolescent and young adult, Hematopoietic stem cell, Clinical Sciences, Immunology, Cardiovascular medicine and haematology
Abstract

Adult hematopoietic stem cell transplantation (HSCT) recipients are at a high risk of adverse outcomes after COVID-19. Although children have had better outcomes after COVID-19 compared to adults, data on risk factors and outcomes of COVID-19 among pediatric HSCT recipients are lacking. We describe outcomes of HSCT recipients who were ≤21 years of age at COVID-19 diagnosis and were reported to the Center for International Blood and Marrow Transplant Research between March 27, 2020, and May 7, 2021. The primary outcome was overall survival after COVID-19 diagnosis. We determined risk factors of COVID-19 as a secondary outcome in a subset of allogeneic HSCT recipients. A total of 167 pediatric HSCT recipients (135 allogeneic; 32 autologous HSCT recipients) were included. Median time from HSCT to COVID-19 was 15 months (interquartile range [IQR] 7-45) for allogeneic HSCT recipients and 16 months (IQR 6-59) for autologous HSCT recipients. Median follow-up from COVID-19 diagnosis was 53 days (range 1-270) and 37 days (1-179) for allogeneic and autologous HSCT recipients, respectively. Although COVID-19 was mild in 87% (n = 146/167), 10% (n = 16/167) of patients required supplemental oxygen or mechanical ventilation. The 45-day overall survival was 95% (95% confidence interval [CI], 90-99) and 90% (74-99) for allogeneic and autologous HSCT recipients, respectively. Cox regression analysis showed that patients with a hematopoietic cell transplant comorbidity index (HCT-CI) score of 1-2 were more likely to be diagnosed with COVID-19 (hazard ratio 1.95; 95% CI, 1.03-3.69, P = .042) compared to those with an HCT-CI of 0. Pediatric and early adolescent and young adult HSCT recipients with pre-HSCT comorbidities were more likely to be diagnosed with COVID-19. Overall mortality, albeit higher than the reported general population estimates, was lower when compared with previously published data focusing on adult HSCT recipients.

Published
2022

5. Post-Transplantation Cyclophosphamide Is Associated with an Increase in Non-Cytomegalovirus Herpesvirus Infections in Patients with Acute Leukemia and Myelodysplastic Syndrome

Author

Singh, Anurag, Dandoy, Christopher E, Chen, Min, Kim, Soyoung, Mulroney, Carolyn M, Kharfan-Dabaja, Mohamed A, Ganguly, Siddhartha, Maziarz, Richard T, Kanakry, Christopher G, Kanakry, Jennifer A, Patel, Sagar S, Hill, Joshua A, De Oliveir, Satiro, Taplitz, Randy, Hematti, Peiman, Lazarus, Hillard M, Abid, Muhammad Bilal, Goldsmith, Scott R, Romee, Rizwan, Komanduri, Krishna V, Badawy, Sherif M, Friend, Brian D, Beitinjaneh, Amer, Politikos, Ioannis, Perales, Miguel-Angel, and Riches, Marcie

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Immunology, Rare Diseases, Cancer, Clinical Research, Stem Cell Research - Nonembryonic - Human, Hematology, Stem Cell Research, Transplantation, Infectious Diseases, Infection, Inflammatory and immune system, Good Health and Well Being, Cyclophosphamide, Cytomegalovirus Infections, Herpesviridae, Humans, Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, Prospective Studies, Non-CMV herpesvirus, Post-transplantation, cyclophosphamide, Haploidentical, Epstein-Barr virus, HHV-6, Post-transplantation cyclophosphamide, Clinical Sciences, Cardiovascular medicine and haematology
Abstract

The use of post-transplantation cyclophosphamide (PTCy) for graft-versus-host disease (GVHD) prophylaxis in recipients of haploidentical and fully matched transplantations is on the increase. Published studies have reported an increased incidence of cytomegalovirus (CMV) infection with the use of PTCy. Limited data exist on the incidence and outcomes of infection with non-CMV herpesviruses (NCHV) in this setting. The aim of this study was to evaluate the cumulative incidence of NCHV infections and the association of NCHV infections with transplantation-specific outcomes in recipients of haploidentical transplantation with PTCy (HaploCy), matched sibling donor transplantation with PTCy (SibCy), and matched sibling donor transplantation with calcineurin inhibitor-based prophylaxis (SibCNI). We hypothesized that, like CMV infection, HaploCy recipients of also will have a higher risk of NCHV infections. Using the Center for International Blood and Marrow Transplantation Research database, we analyzed 2765 patients (HaploCy, n = 757; SibCNI, n = 1605; SibCy, n = 403) who had undergone their first hematopoietic stem cell transplantation (HCT) between 2012 and 2017 for acute myelogenous leukemia, acute lymphoblastic leukemia, or myelodysplastic syndrome. The cumulative incidence of NCHV at 6 months post-NCT was 13.9% (99% confidence interval], 10.8% to 17.3%) in the HaploCy group, 10.7% (99% CI, 7.1% to 15%) in the SibCy group, and 5.7% (99% CI, 4.3% to 7.3%) in the Sib CNI group (P < .001). This was due primarily to a higher frequency of human herpesvirus 6 viremia reported in patients receiving PTCy. The incidence of Epstein-Barr viremia was low in all groups, and no cases of post-transplantation lymphoproliferative disorder were seen in either PTCy group. The incidence of NCHV organ disease was low in all 3 cohorts. The development of NCHV infection was associated with increased treatment-related mortality, particularly in the HaploCy group. There was no association with the development of GVHD, relapse, or disease-free survival. Patients in PTCy cohorts who did not develop NCHV infection had lower rates of cGVHD. This study demonstrates that the use of PTCy is associated with an increased risk of NCHV infection. The development of NCHV infection was associated with increased nonrelapse mortality, especially in the HaploCy group. Prospective trials should consider viral surveillance strategies in conjunction with assessment of immune reconstitution for a better understanding of the clinical relevance of viral reactivation in different HCT settings.

Published
2022

6. The incidence and impact of clostridioides difficile infection on transplant outcomes in acute leukemia and MDS after allogeneic hematopoietic cell transplant—a CIBMTR study

Author

Ramanathan, Muthalagu, Kim, Soyoung, He, Naya, Chen, Min, Hematti, Peiman, Abid, Muhammad Bilal, Rotz, Seth J., Williams, Kirsten M., Lazarus, Hillard M., Wirk, Baldeep, Yin, Dwight E., Kanakry, Christopher G., Perales, Miguel-Angel, Chemaly, Roy F., Dandoy, Christopher E., Riches, Marcie, and Ustun, Celalettin

Published
2023
Full Text
View/download PDF

7. Incidence and impact of community respiratory viral infections in post‐transplant cyclophosphamide‐based graft‐versus‐host disease prophylaxis and haploidentical stem cell transplantation

Author

Mulroney, Carolyn M, Abid, Muhammad Bilal, Bashey, Asad, Chemaly, Roy F, Ciurea, Stefan O, Chen, Min, Dandoy, Christopher E, Perez, Miguel A Diaz, Friend, Brian D, Fuchs, Ephraim, Ganguly, Siddhartha, Goldsmith, Scott R, Kanakry, Christopher G, Kim, Soyoung, Komanduri, Krishna V, Krem, Maxwell M, Lazarus, Hillard M, Ljungman, Per, Maziarz, Richard, Nishihori, Taiga, Patel, Sagar S, Perales, Miguel‐Angel, Romee, Rizwan, Singh, Anurag K, Wingard, John Reid, Yared, Jean, Riches, Marcie, and Taplitz, Randy

Subjects
Prevention, Transplantation, Lung, Stem Cell Research - Nonembryonic - Human, Stem Cell Research, Hematology, Rare Diseases, Organ Transplantation, Orphan Drug, Cancer, Infection, Good Health and Well Being, Adolescent, Adult, Aged, Aged, 80 and over, Child, Child, Preschool, Community-Acquired Infections, Cyclophosphamide, Female, Graft vs Host Disease, HLA Antigens, Hematopoietic Stem Cell Transplantation, Humans, Immunosuppressive Agents, Incidence, Kaplan-Meier Estimate, Leukemia, Living Donors, Male, Middle Aged, Myelodysplastic Syndromes, Proportional Hazards Models, Respiratory Tract Infections, Retrospective Studies, Siblings, Transplantation, Haploidentical, Virus Diseases, Young Adult, Respiratory viral infection, Post Transplant Cyclophosphamide, Allogeneic transplant, Cardiorespiratory Medicine and Haematology, Immunology
Abstract

Community respiratory viral infections (CRVIs) are associated with pulmonary function impairment, alloimmune lung syndromes and inferior survival in human leucocyte antigen (HLA)-matched allogeneic haematopoietic stem cell transplant (HCT) recipients. Although the incidence of viral infections in HLA-haploidentical HCT recipients who receive post-transplant cyclophosphamide (PTCy)-based graft-versus-host disease (GVHD) prophylaxis is reportedly increased, there are insufficient data describing the incidence of CRVIs and the impact of donor source and PTCy on transplant outcomes. Analysing patients receiving their first HCT between 2012 and 2017 for acute myeloid leukaemia, acute lymphoblastic leukaemia and myelodysplastic syndromes, we describe comparative outcomes between matched sibling transplants receiving either calcineurin-based GVHD prophylaxis (SibCNI, N = 1605) or PTCy (SibCy, N = 403), and related haploidentical transplants receiving PTCy (HaploCy, N = 757). The incidence of CRVIs was higher for patients receiving PTCy, regardless of donor type. Patients in the HaploCy cohort who developed a CRVI by day +180 had both a higher risk of treatment-related mortality [hazard ratio (HR) 2⋅14, 99% confidence interval (CI) 1⋅13-4⋅07; P = 0⋅002] and inferior 2-year overall survival (HR 1⋅65, 99% CI 1⋅11-2⋅43; P = 0⋅001) compared to SibCNI with no CRVI. This finding justifies further research into long-term antiviral immune recovery, as well as development of preventive and treatment strategies to improve long-term outcomes in such patients.

Published
2021

8. Comparison of total body irradiation versus non-total body irradiation containing regimens for de novo acute myeloid leukemia in children

Author

Dandoy, Christopher E, Davies, Stella M, Ahn, Kwang Woo, He, Yizeng, Kolb, Anders E, Levine, John, Bo-Subait, Stephanie, Abdel-Azim, Hisham, Bhatt, Neel, Chewing, Joseph, Gadalla, Shahinaz, Gloude, Nicholas, Hayashi, Robert, Lalefar, Nahal R, Law, Jason, MacMillan, Margaret, O’Brien, Tracy, Prestidge, Timothy, Sharma, Akshay, Shaw, Peter, Winestone, Lena, and Eapen, Mary

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Clinical Sciences, Hematology, Traumatic Brain Injury (TBI), Traumatic Head and Spine Injury, Physical Injury - Accidents and Adverse Effects, Brain Disorders, Transplantation, Rare Diseases, Pediatric, Cancer, Busulfan, Child, Cyclophosphamide, Graft vs Host Disease, Hematopoietic Stem Cell Transplantation, Humans, Leukemia, Myeloid, Acute, Retrospective Studies, Transplantation Conditioning, Whole-Body Irradiation, Cardiorespiratory Medicine and Haematology, Immunology, Cardiovascular medicine and haematology
Abstract

With limited data comparing hematopoietic cell transplant outcomes between myeloablative total body irradiation (TBI) containing and non-TBI regimens in children with de novo acute myeloid leukemia, the aim of this study was to compare transplant-outcomes between these regimens. Cox regression models were used to compare transplant-outcomes after TBI and non-TBI regimens in 624 children transplanted between 2008 and 2016. Thirty two percent (n=199) received TBI regimens whereas 68% (n=425) received non-TBI regimens. Five-year non-relapse mortality was higher with TBI regimens (22% vs. 11%, p

Published
2021

9. A pragmatic multi-institutional approach to understanding transplant-associated thrombotic microangiopathy after stem cell transplant

Author

Dandoy, Christopher E, Rotz, Seth, Alonso, Priscila Badia, Klunk, Anna, Desmond, Catherine, Huber, John, Ingraham, Hannah, Higham, Christine, Dvorak, Christopher C, Duncan, Christine, Schoettler, Michelle, Lehmann, Leslie, Cancio, Maria, Killinger, James, Davila, Blachy, Phelan, Rachel, Mahadeo, Kris M, Khazal, Sajad, Lalefar, Nahal, Vissa, Madhav, Myers, Kasiani, Wallace, Greg, Nelson, Adam, Khandelwal, Pooja, Bhatla, Deepika, Gloude, Nicholas, Anderson, Eric, Huo, Jeffrey, Roehrs, Philip, Auletta, Jeffery J, Chima, Ranjit, Lane, Adam, Davies, Stella M, and Jodele, Sonata

Subjects
Prevention, Clinical Research, Pediatric, Regenerative Medicine, Clinical Trials and Supportive Activities, Transplantation, Cancer, Child, Hematopoietic Stem Cell Transplantation, Humans, Incidence, Male, Prospective Studies, Retrospective Studies, Thrombotic Microangiopathies
Abstract

Transplant-associated thrombotic microangiopathy (TA-TMA) is a severe complication of hematopoietic stem cell transplantation (HSCT). A single-center prospective screening study has shown that the incidence of TA-TMA is much higher than prior retrospective studies that did not systematically screen. These data have not been replicated in a multicenter study. Our objective was to determine the incidence and risk factors for TA-TMA and compare outcomes of pediatric HSCT patients with and without TA-TMA. Patients were prospectively screened for TA-TMA at participating centers using a simple to implement and inexpensive strategy from the start of the preparative regimen through day +100. TA-TMA was diagnosed if ≥4 of 7 laboratory/clinical markers diagnostic for TA-TMA were present concurrently or if tissue histology showed TA-TMA. A total of 614 patients (359 males; 58%) received prospective TA-TMA screening at 13 pediatric centers. TA-TMA was diagnosed in 98 patients (16%) at a median of 22 days (interquartile range, 14-44) posttransplant. Patients with TA-TMA had significantly increased bloodstream infections (38% [37/98] vs 21% [107/51], P ≤ .001), mean total hospitalization days (68; 95% confidence interval [CI], 63-74 vs 43; 95% CI, 41-45; P ≤ .001), and number of days spent in the intensive care unit (10.1; 95% CI, 6.4-14; vs 1.6; 95% CI, 1.1-2.2; P ≤ .001) in the first 100 days after HSCT compared with patients without TA-TMA. Overall survival was significantly higher in patients without TA-TMA (93%; 490/516) compared with patients with TA-TMA (78%; 76/98) (P ≤ .001). These data support the need for systematic screening for TA-TMA and demonstrate the feasibility and efficacy of an easy to implement strategy to do so.

Published
2021

12. Bacterial blood stream infections (BSIs), particularly post-engraftment BSIs, are associated with increased mortality after allogeneic hematopoietic cell transplantation

Author

Ustun, Celalettin, Young, Jo-Anne H, Papanicolaou, Genovefa A, Kim, Soyoung, Ahn, Kwang Woo, Chen, Min, Abdel-Azim, Hisham, Aljurf, Mahmoud, Beitinjaneh, Amer, Brown, Valerie, Cerny, Jan, Chhabra, Saurabh, Kharfan-Dabaja, Mohamed A, Dahi, Parastoo B, Daly, Andrew, Dandoy, Christopher E, Dvorak, Christopher C, Freytes, Cesar O, Hashmi, Shahrukh, Lazarus, Hillard, Ljungman, Per, Nishihori, Taiga, Page, Kristin, Pingali, Sai RK, Saad, Ayman, Savani, Bipin N, Weisdorf, Daniel, Williams, Kirsten, Wirk, Baldeep, Auletta, Jeffery J, Lindemans, Caroline A, Komanduri, Krishna, and Riches, Marcie

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Clinical Research, Hematology, Good Health and Well Being, Adolescent, Adult, Bacteremia, Child, Female, Hematopoietic Stem Cell Transplantation, Humans, Male, Middle Aged, Mortality, Risk Factors, Transplantation Conditioning, Transplantation, Homologous, Young Adult, Oncology and Carcinogenesis, Immunology, Cardiovascular medicine and haematology, Oncology and carcinogenesis
Abstract

We analyzed CIBMTR data to evaluate the incidence of non-relapse mortality (NRM) and association with overall survival (OS) for bacterial blood stream infections (BSIs) occurring within 100 days of alloHCT in 2 different phases: pre-/peri-engraftment (BSI very early phase, BSI-VEP) and BSI post-engraftment (BSI occurring between 2 weeks after engraftment and day 100, late early phase, BSI-LEP). Of the 7128 alloHCT patients, 2656 (37%) had ≥1 BSI by day 100. BSI-VEP, BSI-LEP, and BSI-Both constituted 56% (n = 1492), 31% (n = 824), and 13% (n = 340) of total BSI, respectively. Starting in 2009, we observed a gradual decline in BSI incidence through 2012 (61-48%). Patients with BSI-VEP were more likely to receive a myeloablative conditioning (MAC) regimen with total body irradiation (TBI). NRM was significantly higher in patients with any BSI (RR 1.82 95% CI 1.63-2.04 for BSI-VEP, RR 2.46, 95% CI 2.05-2.96 for BSI-LEP, and RR 2.29, 95% CI 1.87-2.81 for BSI-Both) compared with those without BSI. OS was significantly lower in patients with any BSI compared with patients without BSI (RR 1.36, 95% CI 1.26-1.47 for BSI-VEP; RR 1.83, 95% CI 1.58-2.12 for BSI-LEP: RR 1.66, 95% CI 1.43-1.94 for BSI-Both). BSIs within day 100 after alloHCT are common and remain a risk factor for mortality.

Published
2019

15. Levofloxacin prophylaxis in pediatric oncology and hematopoietic stem cell transplantation: a literature review.

Author

Koo, Jane, Hord, Jeffrey, Gilliam, Craig, Rae, Mary Lynn, Staubach, Katherine, Nowacki, Katherine, Lyren, Anne, Coffey, Maitreya, and Dandoy, Christopher E.

Subjects
HEMATOPOIETIC stem cell transplantation, PEDIATRIC oncology, CHILD patients, LITERATURE reviews, YOUNG adults
Abstract

Bloodstream infections (BSI) are one of the leading causes of morbidity and mortality in children and young adults receiving chemotherapy for malignancy or undergoing hematopoietic stem cell transplantation (HSCT). Antibiotic prophylaxis is commonly used to decrease the risk of BSI; however, antibiotics carry an inherent risk of complications. The aim of this manuscript is to review levofloxacin prophylaxis in pediatric oncology patients and HSCT recipients. We reviewed published literature on levofloxacin prophylaxis to prevent BSI in pediatric oncology patients and HSCT recipients. Nine manuscripts were identified. The use of levofloxacin is indicated in neutropenic children and young adults receiving intensive chemotherapy for leukemia or undergoing HSCT. These results support the efficacy of levofloxacin in pediatric patients with leukemia receiving intensive chemotherapy and should be considered in pediatric patients undergoing HSCT prior to engraftment. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

16. Reduced-Intensity Conditioning Mitigates Risk for Primary Ovarian Insufficiency but Does Not Decrease Risk for Infertility in Pediatric and Young Adult Survivors of Hematopoietic Stem Cell Transplantation

Author

Bender, Jonathan D., Toro, Helen Oquendo-del, Benoit, Janie, Howell, Jonathan C., Badia, Priscila, Davies, Stella M., Grimley, Michael S., Jodele, Sonata, Phillips, Christine, Burns, Karen, Marsh, Rebecca, Nelson, Adam, Wallace, Gregory, Dandoy, Christopher E., Pate, Abigail, Strine, Andrew C., Frias, Olivia, Breech, Lesley, Rose, Susan R., Hoefgen, Holly, Khandelwal, Pooja, and Myers, Kasiani C.

Published
2022
Full Text
View/download PDF

20. Incidence and Impact of Fungal Infections in Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis and Haploidentical Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Analysis

Author

Papanicolaou, Genovefa A., Chen, Min, He, Naya, Martens, Michael J., Kim, Soyoung, Batista, Marjorie V., Bhatt, Neel S., Hematti, Peiman, Hill, Joshua A., Liu, Hongtao, Nathan, Sunita, Seftel, Matthew D., Sharma, Akshay, Waller, Edmund K., Wingard, John R., Young, Jo-Anne H., Dandoy, Christopher E., Perales, Miguel-Angel, Chemaly, Roy F., Riches, Marcie, and Ustun, Celalettin

Published
2024
Full Text
View/download PDF

21. Daytime-restricted parenteral feeding is associated with earlier oral intake in children following stem cell transplant

Author

Wang, YunZu Michele, Taggart, Cynthia B., Huber, John F., Davies, Stella M., Smith, David F., Hogenesch, John B., and Dandoy, Christopher E.

Subjects
Parenteral feeding -- Methods -- Patient outcomes, Parenteral therapy -- Methods -- Patient outcomes, Hematopoietic stem cells -- Transplantation, Pediatric research, Health care industry
Abstract

To the editor: In inpatients unable to sustain themselves enterally, standard i.v. total parenteral nutrition (TPN) is often administered over a 20- to 24-hour feeding period. However, feeding time is [...]

Published
2023
Full Text
View/download PDF

22. Increased Body Mass Index Augments Endothelial Injury and Clinical Outcomes after Hematopoietic Stem Cell Transplantation

Author

Koo, Jane, Ziady, Assem G., Reynaud, Damien, Abdullah, Sheyar, Luebbering, Nathan, Kahn, Seth, Langenberg, Lucille, Strecker, Lauren, Lake, Kelly, Dandoy, Christopher E., Lane, Adam, Myers, Kasiani C., Sabulski, Anthony, Good, Samantha, Nalapareddy, Kodandaramireddy, Solomon, Michael, Siefert, Matthew E., Skala, Emily, Jodele, Sonata, and Davies, Stella M.

Published
2023
Full Text
View/download PDF

24. In Pursuit of Optimal Outcomes: A Framework for Quality Standards in Immune Effector Cell Therapy

Author

Dandoy, Christopher E, Adams, Joan, Artz, Andrew, Bredeson, Christopher, Dahi, Parastoo B., Dodd, Therese, Jaglowski, Samantha, Lehmann, Leslie, LeMaistre, Charles F., Mian, Amir, Neal, Alison, Page, Kristen, Rizzo, J. Douglas, Rotz, Seth, Sorror, Mohamed, Steinberg, Amir, Viswabandya, Auro, and Howard, Dianna S.

Abstract

•The article outlines a comprehensive framework for quality standards in IEC therapy, emphasizing structured process measures, quality assurance, and outcome evaluation.•The article reviews the crucial role of collaboration among patients, healthcare providers, payers, manufacturers, and regulatory bodies in delivering high-quality IEC therapies.•Standardized reporting and accreditation by bodies like CIBMTR, FACT, and JACIE are essential for ensuring the effectiveness, safety, and continuous improvement of IEC therapies.

Published
2024
Full Text
View/download PDF

25. Neighborhood poverty and pediatric allogeneic hematopoietic cell transplantation outcomes: a CIBMTR analysis

Author

Bona, Kira, Brazauskas, Ruta, He, Naya, Lehmann, Leslie, Abdel-Azim, Hisham, Ahmed, Ibrahim A, Al-Homsi, A Samer, Aljurf, Mahmoud, Arnold, Staci D., Badawy, Sherif M, Battiwalla, Minoo, Beattie, Sara, Bhatt, Neel S., Dalal, Jignesh, Dandoy, Christopher E., Diaz, Miguel Angel, Frangoul, Haydar A., Freytes, César O., Ganguly, Siddhartha, George, Biju, Gomez-Almaguer, David, Hahn, Theresa, Kamble, Rammurti T., Knight, Jennifer M., LeMaistre, C. Fred, Law, Jason, Lazarus, Hillard M., Majhail, Navneet S., Olsson, Richard F., Preussler, Jaime, Savani, Bipin N., Schears, Raquel, Seo, Sachiko, Sharma, Akshay, Srivastava, Alok, Steinberg, Amir, Szwajcer, David, Wirk, Baldeep, Yoshimi, Ayami, Khera, Nandita, Wood, William A., Hashmi, Shahrukh, Duncan, Christine N., and Saber, Wael

Published
2021
Full Text
View/download PDF

26. Real-World Issues and Potential Solutions in Hematopoietic Cell Transplantation during the COVID-19 Pandemic: Perspectives from the Worldwide Network for Blood and Marrow Transplantation and Center for International Blood and Marrow Transplant Research Health Services and International Studies Committee

Author

Algwaiz, Ghada, Aljurf, Mahmoud, Koh, Mickey, Horowitz, Mary M., Ljungman, Per, Weisdorf, Daniel, Saber, Wael, Kodera, Yoshihisa, Szer, Jeff, Jawdat, Dunia, Wood, William A., Brazauskas, Ruta, Lehmann, Leslie, Pasquini, Marcelo C., Seber, Adriana, Lu, Pei Hua, Atsuta, Yoshiko, Riches, Marcie, Perales, Miguel-Angel, Worel, Nina, Okamoto, Shinichiro, Srivastava, Alok, Chemaly, Roy F., Cordonnier, Catherine, Dandoy, Christopher E., Wingard, John R., Kharfan-Dabaja, Mohamed A., Hamadani, Mehdi, Majhail, Navneet S., Waghmare, Alpana A., Chao, Nelson, Kröger, Nicolaus, Shaw, Bronwen, Mohty, Mohamad, Niederwieser, Dietger, Greinix, Hildegard, and Hashmi, Shahrukh K.

Published
2020
Full Text
View/download PDF

27. The Impact of Donor Type on Outcomes and Cost of Allogeneic Hematopoietic Cell Transplantation for Pediatric Leukemia: A Merged Center for International Blood and Marrow Transplant Research and Pediatric Health Information System Analysis

Author

Arnold, Staci D., Brazauskas, Ruta, He, Naya, Li, Yimei, Hall, Matt, Atsuta, Yoshiko, Dalal, Jignesh, Hahn, Theresa, Khera, Nandita, Bonfim, Carmem, Hashmi, Shahrukh, Parsons, Susan, Wood, William A., Steinberg, Amir, Freytes, César O., Dandoy, Christopher E., Marks, David I., Lazarus, Hillard M., Abdel-Azim, Hisham, Bitan, Menachem, Diaz, Miguel Angel, Olsson, Richard F., Gergis, Usama, Seber, Adriana, Wirk, Baldeep, LeMaistre, C. Fred, Ustun, Celalettin, Duncan, Christine, Rizzieri, David, Szwajcer, David, Fagioli, Franca, Frangoul, Haydar, Knight, Jennifer M., Kamble, Rammurti T., Mehta, Paulette, Schears, Raquel, Satwani, Prakash, Pulsipher, Michael A., Aplenc, Richard, and Saber, Wael

Published
2020
Full Text
View/download PDF

28. Improving Oral Health and Modulating the Oral Microbiome to Reduce Bloodstream Infections from Oral Organisms in Pediatric and Young Adult Hematopoietic Stem Cell Transplantation Recipients: A Randomized Controlled Trial

Author

Badia, Priscila, Andersen, Heidi, Haslam, David, Nelson, Adam S., Pate, Abigail R., Golkari, Sara, Teusink-Cross, Ashley, Flesch, Laura, Bedel, Ashely, Hickey, Victoria, Kramer, Kathi, Lane, Adam, Davies, Stella M., Thikkurissy, Sarat, and Dandoy, Christopher E.

Published
2020
Full Text
View/download PDF

29. Collection of Peripheral Blood Progenitor Cells in 1 Day Is Associated with Decreased Donor Toxicity Compared to 2 Days in Unrelated Donors

Author

Hsu, Jack W., Shaw, Bronwen E., Kim, Soyoung, Logan, Brent R., Sees, Jennifer A., Confer, Dennis L., Pulsipher, Michael A., Shah, Nirali, Switzer, Galen E., Abidi, Muneer H., Ahmed, Ibrahim A., Anderlini, Paulo N., Bredeson, Christopher, Chhabra, Saurabh, Dandoy, Christopher E., Diaz, Miguel Angel, Farhadfar, Nosha, Ganguly, Siddhartha, Gergis, Usama, Hale, Gregory A., Hematti, Peiman, Kamble, Rammurti T., Kasow, Kimberly A., Lazarus, Hillard M., Liesveld, Jane L., Murthy, Hemant S., Olsson, Richard F., Savani, Bipin N., Schears, Raquel, Seo, Sachiko, Solh, Melhern, Spitzer, Thomas, Steinberg, Amir, Sugrue, Michele, Warkentin, Phyllis, and Wingard, John R.

Published
2020
Full Text
View/download PDF

43. Post-transplantation cyclophosphamide is associated with increased bacterial infections

Author

Ustun, Celalettin, primary, Chen, Min, additional, Kim, Soyoung, additional, Auletta, Jeffery J., additional, Batista, Marjorie V., additional, Battiwalla, Minoo, additional, Cerny, Jan, additional, Gowda, Lohith, additional, Hill, Joshua A., additional, Liu, Hongtao, additional, Munshi, Pashna N., additional, Nathan, Sunita, additional, Seftel, Matthew D., additional, Wingard, John R., additional, Chemaly, Roy F., additional, Dandoy, Christopher E., additional, Perales, Miguel-Angel, additional, Riches, Marcie, additional, and Papanicolaou, Genovefa A., additional

Published
2023
Full Text
View/download PDF

44. Incidence and impact of fungal infections in post-transplant Cyclophosphamide (PTCy)-based graft-versus-host disease prophylaxis and haploidentical hematopoietic cell transplantation: A CIBMTR analysis

Author

Papanicolaou, Genovefa A., primary, Chen, Min, additional, He, Naya, additional, Martens, Michael J., additional, Kim, Soyoung, additional, Batista, Marjorie V., additional, Bhatt, Neel S., additional, Hematti, Peiman, additional, Hill, Joshua A., additional, Liu, Hongtao, additional, Nathan, Sunita, additional, Seftel, Matthew D., additional, Sharma, Akshay, additional, Waller, Edmund K., additional, Wingard, John R., additional, Young, Jo-Anne H., additional, Dandoy, Christopher E., additional, Perales, Miguel-Angel, additional, Chemaly, Roy F., additional, Riches, Marcie, additional, and Ustun, Celalettin, additional

Published
2023
Full Text
View/download PDF

48. Choosing Wisely BMT: American Society for Blood and Marrow Transplantation and Canadian Blood and Marrow Transplant Group's List of 5 Tests and Treatments to Question in Blood and Marrow Transplantation

Author

Bhella, Sita, Majhail, Navneet S., Betcher, Jeffrey, Costa, Luciano J., Daly, Andrew, Dandoy, Christopher E., DeFilipp, Zachariah, Doan, Vi, Gulbis, Alison, Hicks, Lisa, Juckett, Mark, Khera, Nandita, Krishnan, Amrita, Selby, George, Shah, Nirav N., Stricherz, Melisa, Viswabandya, Auro, Bredeson, Christopher, and Seftel, Matthew D.

Published
2018
Full Text
View/download PDF

50. Diffuse alveolar hemorrhage after hematopoietic cell transplantation- response to treatments and risk factors for mortality

Author

Schoettler, Michelle L., primary, Dandoy, Christopher E., additional, Harris, Anora, additional, Chan, Marilynn, additional, Tarquinio, Keiko M., additional, Jodele, Sonata, additional, Qayed, Muna, additional, Watkins, Benjamin, additional, Kamat, Pradip, additional, Petrillo, Toni, additional, Obordo, Jeremy, additional, Higham, Christine S., additional, Dvorak, Christopher C., additional, Westbrook, Adrianna, additional, Zinter, Matt S., additional, and Williams, Kirsten M., additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results